Autologous Cell Therapy Market

Table of Content

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Introduction

2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Healthcare Providers

2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach

3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis

3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation

3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Autologous Cell Therapy
6.2.1. Key Characteristics of Autologous Cell Therapy
6.2.2. Key Applications of the Autologous Cell Therapy
6.2.3. Challenges Associated with Autologous Cell Therapy

6.3. Future Perspective

7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. Autologous Cell Therapy Providers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size

7.2.3. Autologous Cell Therapy: Overall Market Landscape
7.2.3.1. Analysis by Therapy Type
7.2.3.2. Analysis by Source Type
7.2.3.3. Analysis by Product Type
7.2.3.4. Analysis by Application
7.2.3.5. Analysis by End Users

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodologies

8.4. Company Competitiveness Analysis: Autologous Cell Therapy Providers
8.4.1. Autologous Cell Therapy Providers Based in North America (Peer Group 1)
8.4.2. Autologous Cell Therapy Providers Based in Europe (Peer Group 2)
8.4.3. Autologous Cell Therapy Providers Based in Asia-Pacific (Peer Group 3)
8.4.4. Autologous Cell Therapy Providers Based in Middle East and North Africa, and Rest of the World (Peer Group 4)

8.5. Key Findings

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Anterogen
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service / Product Portfolio
9.2.4. Recent Developments and Future Outlook

* Similar detail is presented for other below mentioned companies based on information in the public domain

9.3. Adaptive Immunotherapeutics
9.4. AgonOx
9.5. Avotres
9.6. Bristol-Myers Squibb Company
9.7. Biocardia
9.8. CARsgen Therapeutics
9.9. Gilead Sciences
9.10. Holostem
9.11. Iovance Biotherapeutics
9.12. IASO BioTherapeutics
9.13. ImmunoAdoptive Cell Therapy (ImmunoACT)
9.14. Johnson & Johnson
9.15. JW (Cayman) Therapeutics
9.16. Kyverna Therapeutics
9.17. Novartis
9.18. Obsidian Therapeutics
9.19. Pharmicell
9.20. Vericel

10. SWOT ANALYSIS

11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
11.6. Conclusion

12. GLOBAL AUTOLOGOUS CELL THERAPY MARKET
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Trends Disruption Impacting Market
12.4. Global Autologous Cell Therapy, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

12.5. Multivariate Scenario Analysis
12.5.1. Conservative Scenario
12.5.2. Optimistic Scenario

12.6. Key Market Segmentations

13. MARKET OPPORTUNITIES BASED ON TYPE OF THERAPY
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Revenue Shift Analysis
13.4. Market Movement Analysis
13.5. Penetration-Growth (P-G) Matrix
13.6. Autologous Cell Therapy Market for Autologous Stem Cell: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
13.7. Autologous Cell Therapy Market for Autologous Non-Stem Cell: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
13.8. Data Triangulation and Validation

14. MARKET OPPORTUNITIES BASED ON TYPE OF SOURCE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Revenue Shift Analysis
14.4. Market Movement Analysis
14.5. Penetration-Growth (P-G) Matrix
14.6. Autologous Cell Therapy Market for T-Cells: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.7. Autologous Cell Therapy Market for Mesenchymal Cells: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.8. Data Triangulation and Validation

15. MARKET OPPORTUNITIES BASED ON TYPE OF PRODUCT
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. Autologous Cell Therapy Market for Cellular Therapy Products: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.7. Autologous Cell Therapy Market for Recombinant Proteins: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.8. Autologous Cell Therapy Market for Gene Therapy Products: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.9. Autologous Cell Therapy Market for By-Products: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.10. Data Triangulation and Validation

16. MARKET OPPORTUNITIES BASED ON TYPE OF APPLICATION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. Autologous Cell Therapy Market for Autoimmune Diseases: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.7. Autologous Cell Therapy Market for Cancer: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.8. Autologous Cell Therapy Market for Neurodegenerative Disorders: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.9. Autologous Cell Therapy Market for Cardiovascular Diseases: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.10. Autologous Cell Therapy Market for Orthopedic Diseases: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.11. Autologous Cell Therapy Market for Other Applications: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.12. Data Triangulation and Validation

17. MARKET OPPORTUNITIES BASED ON END USER
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. Autologous Cell Therapy Market for Hospitals: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.7. Autologous Cell Therapy Market for Ambulatory Surgery Centers: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.8. Autologous Cell Therapy Market for Research Facilities: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.9. Autologous Cell Therapy Market for Other End Users: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.10. Data Triangulation and Validation

18. MARKET OPPORTUNITIES FOR AUTOLOGOUS CELL THERAPY IN NORTH AMERICA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix

18.6. Autologous Cell Therapy Market in North America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.6.1. Autologous Cell Therapy Market in the US: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.6.2. Autologous Cell Therapy Market in Canada: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.6.3. Autologous Cell Therapy Market in Mexico: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

18.7. Data Triangulation and Validation

19. MARKET OPPORTUNITIES FOR AUTOLOGOUS CELL THERAPY IN EUROPE
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix

19.6. Autologous Cell Therapy Market in Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.6.1. Autologous Cell Therapy Market in France: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.6.2. Autologous Cell Therapy Market in Germany: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.6.3. Autologous Cell Therapy Market in Italy: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.6.4. Autologous Cell Therapy Market in Spain: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.6.5. Autologous Cell Therapy Market in Rest of the Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

19.7. Data Triangulation and Validation

20. MARKET OPPORTUNITIES FOR AUTOLOGOUS CELL THERAPY IN ASIA-PACIFIC
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix

20.6. Autologous Cell Therapy Market in Asia-Pacific: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.1. Autologous Cell Therapy Market in China: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.2. Autologous Cell Therapy Market in India: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.3. Autologous Cell Therapy Market in Japan: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.4. Autologous Cell Therapy Market in South Korea: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.5. Autologous Cell Therapy Market in Australia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.6. Autologous Cell Therapy Market in Russia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.7. Autologous Cell Therapy Market in Thailand: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.8. Autologous Cell Therapy Market in Malaysia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.9. Autologous Cell Therapy Market in Indonesia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.10. Autologous Cell Therapy Market in Rest of the Asia-Pacific: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

20.7. Data Triangulation and Validation

21. MARKET OPPORTUNITIES FOR AUTOLOGOUS CELL THERAPY IN MIDDLE EAST AND NORTH AFRICA (MENA)
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix

21.6. Autologous Cell Therapy Market in Middle East and North Africa (MENA): Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.1. Autologous Cell Therapy Market in Egypt: Historical Trends (Since 2019) and Forecasted Estimates (Till 205)
21.6.2. Autologous Cell Therapy Market in Saudi Arabia: Historical Trends (Since 2019) and Forecasted Estimates (Till 205)
21.6.3. Autologous Cell Therapy Market in United Arab Emirates (UAE): Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

21.7. Data Triangulation and Validation

22. MARKET OPPORTUNITIES FOR AUTOLOGOUS CELL THERAPY IN LATIN AMERICA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix

22.6. Autologous Cell Therapy Market in Latin America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.1. Autologous Cell Therapy Market in Argentina: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.2. Autologous Cell Therapy Market in Brazil: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

22.7. Data Triangulation and Validation

23. TABULATED DATA

24. LIST OF COMPANIES AND ORGANIZATIONS

25. CUSTOMIZATION OPPORTUNITIES

26. ROOTS SUBSCRIPTION SERVICES

27. AUTHOR DETAIL